Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
EAS 2021Do Anti-ApoA-1 Antibodies Link Fatty Liver Disease and CVD?Anti-ApoA-1 antibodies appear to be common in patients with NAFLD and may drive both fat deposits and pro-inflammatory effects in liver cells, although it remains to be seen whether they can be targeted.
Steep, Sustained Lipid Reductions Over Statins With LIB003An open-label trial extension shows the novel anti-PCSK9 recombinant protein LIB003 markedly reduces lipid levels in heavily
pretreated patients, although outcomes data are awaited, says expert.
Medscape Medical News, Oct 09, 2020
Evinacumab Offers 'Remarkable' Lipid Lowering in Severe HoFHHomozygous familial hypercholesterolemia patients with little or no LDL receptor activity had marked and sustained LDL cholesterol
reductions with the antibody evinacumab, ELIPSE trial results show.
Medscape Medical News, Oct 12, 2020
Inclisiran Effectively Lowers LDL Across High-risk SettingsPatients with heterozygous FH, regardless of phenotype, and those at high risk for a first cardiovascular event had huge LDL
cholesterol reductions with inclisiran, the latest ORION data show.
